Another study demonstrated anatomic features related to high complication rate of intracranial angioplasty and stenting, Background and Purpose-To investigate the efficacy and safety of percutaneous transluminal angioplasty and stenting (PTAS) for symptomatic middle cerebral artery stenosis compared with standard medical treatment in a low-risk Chinese population. Methods-A prospective, randomized, controlled, single-center clinical trial was conducted comparing PTAS with medical treatment for symptomatic middle cerebral artery stenosis (≥70%). Patients were enrolled according to 1:1 enroll ratio (PTAS: medical). The PTAS group received stenting or balloon angioplasty, whereas the medical treatment group received standard medical treatment (aspirin 100 mg plus clopidogrel 75 mg/d), and all the patients were under strict control of the risk factors. The end point events were any kind of ipsilateral stroke or transient ischemic attack, or death from any origin during 1-year follow-up. Results-The enrollment was stopped after 70 patients were enrolled from August 2007 to December 2010, with a 30-day rate of end point events of 8.3% versus 5.9% (P=0.69) for PTAS and medical group, respectively, and 1-year rate of end point events of 19.4% versus 17.6% (P=0.85), respectively. There was no significant difference in baseline characteristics between the 2 groups. The mean follow-up time, which was ongoing, was 9.9 ± 3.9 and 9.7 ± 4.4 months, respectively. Among the risk factors, hypertension was the independent related to the outcome (P=0.015). Conclusions-This study showed that endovascular treatment is as safe but not better than medical treatment for symptomatic middle cerebral artery stenosis in a low-risk Chinese population. History of hypertension increases the risk of recurrent ischemic events. 
I
ntracranial arterial stenosis accounts for 33% to 50% of ischemic strokes in Asian populations. 1 Although antiplatelets have been recognized as the core therapeutic regimen for high-risk patients to prevent the recurrent stroke, [2] [3] [4] the WASID study showed that its beneficial effect for intracranial atherosclerosis (≥70%) is still small, with the 1-year risk of ischemic stroke remaining as high as ≈23%. 5 Alternative treatments, such as percutaneous transluminal angioplasty and stenting (PTAS), have been evaluated for these patients. Case series have shown that PTAS is feasible using existing angioplasty devices, with high technical success rates, low periprocedural complications, and favorable outcomes in selected patients. [6] [7] [8] [9] [10] [11] [12] [13] [14] Although SAMMPRIS trial has found that medical treatment is superior to PTAS, 15 it remains uncertain whether the high periprocedural risk of stroke and death is related to the specific devices used in the trial, operator experience, treatment method, or patient selection.
The middle cerebral artery (MCA) is one of the most common sites involved in symptomatic intracranial atherosclerosis. A previous meta-analysis showed lower complication rates of intracranial angioplasty and stenting in the anterior circulation than in the posterior circulation. which could be avoided by proper patient screening. 17 We hypothesized intracranial angioplasty and stenting plus medical therapy was better than medical therapy alone in patients with symptomatic severe MCA stenosis who are at low risk for endovascular therapy. We started a prospective, randomized, controlled, single-center clinical trial to test this hypothesis in 2007 in Xuanwu Hospital. The enrollment was stopped in December 2010, because the interim analysis showed there was no chance that intervention could be better than medical therapy even after the entire enrollment was finished. Here, we report the results.
Methods

Trial Design
This was a prospective, randomized, controlled, single-center clinical trial to compare the efficacy and safety of PTAS with standard medical treatment for symptomatic MCA stenosis in a Chinese population. The study protocol had been approved by the Ethical Committee of Xuanwu Hospital, and all patients signed informed written consent before randomization. The steering committee, which consisted of Vice President of Research of Xuanwu Hospital, Chief of Neurosurgery and Chief of Neurology, were responsible for the design, safety, and proper conduct of the trial. The quality control committee was led by a neurosurgeon (Y.B.) specialized in surgical treatment of hemorrhagic strokes, blinded to the treatment assignment of patients and was in charge of adjudicating the end points and complications. The data analysis committee, consisted of research associates and statisticians from the Neurosurgery Department and Institute of Biomedical Engineering of Capital University, collected and analyzed data from investigators and reported periodically to the steering committee and quality control committee (Supplemental Appendix).
Patients
All the patients with stroke or transient ischemic attack (TIA) received diagnostic digital subtraction angiography to confirm the stenosis of MCA. Then the patients were enrolled or not according to the inclusion and exclusion criteria (Table 1 and Supplemental  Table 1 ).
Procedures
Patients were randomized to either the PTAS or medical group. For PTAS group, patients took aspirin 300 mg/d and clopidogrel 75 mg/d for 3 days before endovascular treatment. Intracranial angioplasty with or without stenting were performed by 4 experienced neurointerventionists (Z.M., L.J., F.Z., and S.L.), with a combined experience of >500 intracranial stenting before this trial. 14, 18, 19 These patients continued aspirin 100 mg/d for the rest of their life and clopidogrel 75 mg/d for 3 months. Patients in the medical group received aspirin 100 mg/d for the rest of their life and clopidogrel 75 mg/d for 3 months from the day of randomization. For patients who were allergic to either aspirin or clopidogrel, dipyridamole (25 mg po tid) was used as the substitute.
The underlying stroke risk factors, including hypertension, hyperlipidemia, diabetes mellitus, coronary artery disease, homocysteinemia, obesity, smoking, and alcoholism abuse, were evaluated and managed by experienced neurologists. We targeted a systolic blood pressure of <130 mm Hg, fasting glucose level of <6 mmol/L, and a low-density lipoprotein cholesterol level of <70 mg/dL (1.81 mmol/L).
Follow-up
Investigators who did not participate in the enrollment of the patients and were blinded to the treatment assignment followed the patients at 1 month, 3 months, 6 months, and 1 year after randomization, or whenever any end point event occurred, to monitor the changes of symptoms and lifestyle and to evaluate the related blood tests and Transcranial Doppler examination after treatment. Digital subtraction angiography was performed at 1 year or whenever the end point events took place.
End Point Events and Complications
The primary end point was ipsilateral stroke, TIA, or death during the first year, which were assessed by experienced neurologists who were blinded to the treatment assignment and adjudicated by the quality control committee under the steering committee. TIA was defined as a new focal neurological deficit of sudden onset, completely reversed to baseline within 24 hours. TIA was chosen as a primary end point because most Chinese patients with intracranial atherosclerosis present with recurrent TIAs, many of whom eventually suffer major strokes or vascular dementia. 20, 21 The social and psychological impact of TIA on the patient's life is also similar to minor strokes. Several studies on intracranial atherosclerosis included TIA as a primary outcome. 22 Ischemic stroke was defined as a new focal neurological deficit of sudden onset, lasting at least 24 hours, not associated with a hemorrhage on computed tomography or magnetic resonance imaging of the brain. Symptomatic brain hemorrhage is defined as a parenchymal, subarachnoid, or intraventricular hemorrhage detected on computed tomography or magnetic resonance imaging that is associated with a seizure or with new neurological signs or symptoms lasting at least 24 hours.
Statistical Analysis
Sample Size
Because information on MCA stenosis was rather limited in the literature, the sample size calculation was based on the previous studies about intracranial stenosis, which suggested event rates of 5.6% 23 and 23% (WASID trial) 5 for PTAS and medical treatment, respectively. Assuming the same effect size, at least 83 patients per group would be necessary to have a 90% power at a 2-sided α of 0.05. Considering 10% of patients would be lost to follow-up, and a randomized ratio of 1:1, the final enrollment would be 184. The randomization numbers were produced by Randlist software (Version 1.2 \Seed:
[1497369600]; http://www.randomisation.net), 4 numbers as a block.
Data Analysis
All data were analyzed based on intent-to-treat analysis unless otherwise specified. Difference among groups was analyzed by Student t test for continuous data and χ 2 test for categorical data. The contribution of each risk factor to end point event was also evaluated with χ 2 test. 
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Results
Patient Characteristics
Seventy consecutive patients were enrolled from September 2007 to December 2010, from which 36 patients were randomized into PTAS group (31-74 years old; mean 53.4 ± 13.6) and 34 into the medical group (27-70 years old; mean 49.2 ± 9.3). Seven patients in PTAS group refused the endovascular treatment, and 2 patients in medical group insisted having endovascular treatment, resulting 31 patients in PTAS group and 39 in the other. And 63 patients were excluded from this study (data not shown). Among the 70 enrolled, 49 were men (70.4%). The most common qualifying event was TIA (78.6%), and the most patients came for standard treatment late after ischemic attacks (3 days-4 years; mean 5.9 months). Most of the patients were overweight (mean body mass index 25.9 ± 2.6 versus 25.8 ± 3.2, PTAS versus medical treatment, respectively). The most common stroke risk factor was smoking (57.1%), followed by hypertension (54.3%). Most of the patients had mild residual neurological deficits (National Institutes of Health Stroke Scale ≤3, Barthel Index ≥80, and modified Rankin Scale ≤2). The mean stenosis was 83.9 ± 8.13% versus 85 ± 6.74%, and mean length of stenotic segment was 6.25 ± 1.5 versus 6 ± 1.33 mm for PTAS and medical treatment, respectively. There was no significant difference between the 2 groups for all the other baseline characteristics. Table 2 displayed the detailed baseline information.
Outcome
Treatment
All endovascular procedures were successfully completed. In the PTAS group, there were 4 balloon angioplasties (B. Braun, Berlin, Germany), and 25 stentings (1 with PTA Firebird stent, 7 with Wingspan stent system (Boston Scientific, MA), 17 with Coroflex or Coroflex Blue (B. Braun, Berlin Germany). In the medical group, 2 patients underwent endovascular therapy, one with balloon angioplasty, the other with Apollo stent (Minimally Invasive, Shanghai, China). The technical success rate was 100%.
Follow-Up and Reevaluation
All the enrolled patients were followed up until December 2010. The mean follow-up time were 9.9 ± 3.9 and 9.7 ± 4.4 months for PTAS and medical treatment, respectively. All the patients received neurological deficit evaluation. Fortynine patients finished the 1-year follow-up, whereas 13 other patients were terminated for end point events. The Transcranial Doppler reevaluation rate was 87.1% (61/70), and 68.6% (48/70) patients received digital subtraction angiography after finishing the follow-up.
End Points Events
Thirteen end point events occurred during follow-up period, including 2 strokes and 11 TIAs. All the end points events were in the territory of qualifying artery.
End Points Within 30 Days of Treatment
Three end point events occurred within 30 days after treatment in PTAS group (1 disabling ischemic stroke and 2 TIAs) Of the end points in PTAS group, 1 patient had acute hemiplegia on day 3 after the procedure. Emergent Digital subtraction angiography showed acute occlusion of the stented MCA, which was recanalized with intra-arterial thrombolysis using 500 000 IU of urokinase. This patient was noncompliant with antiplatelet medication. One patient with uncontrolled hyperglycemia suffered a TIA on day 5 after the procedure. The third patient had TIA at 18 days after the procedure, 5 days after clopidogrel was switched to dipyridamole because of allergy. In the medical group, one TIA occurred at 7 days after treatment and the other at 20 days without clear aggravating factor.
End Points at 1 Year of Treatment
Seven end point events occurred in the PTAS group (1 disabling ischemic stroke and 6 TIAs) within 1 year and 6 in the medical group (1 disabling ischemic stroke and 5 TIAs) (19.4% versus 17.6%, respectively; P=0.85). One of the TIAs in medical group occurred in a patient who was allergic to aspirin. Two TIAs occurred in patients who were randomized to the PTAS group but shifted to medical group. But there was no difference of end points between the 2 groups for ontreatment analysis.
Related Risk Factors
At the 1-year follow-up, the percentages of patients who reached target level of blood pressure, diabetes mellitus, and hyperlipidemia control were 63.9%, 81.6%, 83.3% for the PTAS group and 71.6%, 94.1%, 88.2% for the medical group, respectively. There was no statistically significant difference in the response rates to medical treatment between the 2 groups. History of hypertension is associated with high risk of end points (P=0.015). Other risk factors (age, gender, body mass index, qualifying events, serum lipid level, blood glucose level, coronary artery diseases, family history, smoking, alcoholism, neurological deficit before treatment, and target lesion characteristics pretreatment) had very little influence on end point events (P>0.05; Table 3 ).
Discussion
This trial shows that endovascular treatment can be performed safely in carefully selected patients with symptomatic MCA stenosis. In this study, the 30-day rate of stroke or death in the PTAS group (2.8%) is substantially lower than the rates recently reported with the use of the Wingspan stent in SAMMPRIS trial (14.7%) 15 and also lower than previously reported in 2 Wingspan registries (rates ranging from 4.4% to 9.6%). 6, 24, 25 Additionally, in this study, all PTAS procedures were successfully performed, and the periprocedural complication rate was 0, which is better than Miao's retrospective study (5.3%) 14 and US multicenter experience (6.1%). 25 A recent systematic review demonstrated that the technical success rate for intracranial high grade stenosis ranges from 90% to 100%, 16 and the periprocedural complication rate ranges from 9.9% to 30%. 9, 10 Five reasons may contribute to the low complication rate in the PTAS group in this study. First, most of the qualifying events were TIAs, and patients with recent strokes were excluded from this trial. Studies have shown that recent stroke is one of the major risk factors for procedural complications, which usually resulted from unstable plaques. 24, 26, 27 Second, the operators are highly experienced, having performed more than 500 intracranial angioplasty and stenting for intracranial atherosclerosis in the 5 years before the trial. In contrast, the SAMMPRIS trial only required the operators to have experience with intracranial stenting, not necessarily for treating intracranial atherosclerosis. Third, patients with high anatomic risks for PTAS have been excluded from the trial. 17 This study includes only M1 stenosis. Basilar artery, which carries a higher procedural risk for stenting according to some authors, are included in SAMMPRIS trial but not in this study. Fourth, the mean age in the PTAS group was 53 years, younger than the SAMMPRIS study, 15 suggesting easier vasculature access for PTAS. Last, most of the stent used in this study were Coroflex or Coroflex blue (54.8%, 17/31). The balloon-mounted stents are more rigid than the Gateway-Wingspan system, but does not require catheter exchange. In patients with good access, the placement of balloon-mounted stent is technically simpler and requires less procedural time. Although the MCA is more difficult to access than other intracranial arteries, 14 with training and careful selection of patients, a high success rate and low periprocedural complication rate can be achieved.
This study shows that endovascular treatment is no better than medical therapy for low-risk patients with symptomatic MCA stenosis. In this trial, the rate of ischemic events in the medical treatment group was much lower than in other studies. Excluding TIA, the 30-day stroke and death rate is 0% and that at 1 year is 2.9%, much lower than WASID 28 and SAMMPRIS trials. 15 There are several reasons contributing to this low risk in the medical arm. First, our patients have a low frequency of hypertension, diabetes mellitus, and hyperlipidemia compared with WASID or SAMMPRIS, likely because of the young age and different diet and lifestyle in the Chinese population. Second, patients with stroke within 3 weeks before enrollment were excluded, and there is a long latency between qualifying event and enrollment. Studies have shown that the risk of recurrent stroke is the highest immediately after the qualifying events and reduces over time. Third, many minor strokes could have been misclassified as TIA because of late clinical evaluation and lack of imaging verification.
Hypertension is the single most important risk factor for recurrent ischemic events. 29 A meta-analysis has showed that lowering of blood pressure can result a 30% to 40% reduction in stroke risk. 30 The posthoc analysis from the WASID trial also showed that the lowering of systolic blood pressure could reduce the risk of stroke. 31, 32 SAMMPRIS trial further indicated that after strict control of these risk factors, the 30-day and 1-year rate of primary end point event in medical group reduced to 5.8% and 12.2%. 15 In this study, history of hypertension was the only independent risk factor (P=0.015) for recurrent ischemic events. We will further analyze the changes of patients' blood pressure before and after treatment, to investigate whether there is some relationship between the blood pressure and outcome.
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December 2012 This study was designed on a subset of patients with intracranial atherosclerosis using clinical information from the general population of patients with intracranial atherosclerosis, with an incomplete follow-up and lack of imaging verification of ischemic events. The study demonstrated that the procedural complications may be reduced with appropriate selection of patients. Future studies should select patients who are at high risk for stroke and low risk for intracranial angioplasty and stenting.
Conclusions
Based on these interim clinical results, endovascular treatment is safe but not better than medical treatment for symptomatic MCA stenosis. Patients with history of hypertension carry a higher risk for recurrent ischemic events.
